Clinical Trials · NCT05696847
A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 28
- Start date
- Feb 2023
- Locations
- 3 sites, United States
- Primary endpoint
- Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)